Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21452019 | 0.88 | DRD2 (0.36) | DRD2KDM4DABCB1 | |
| SCHEMBL21451897 | 0.86 | HDAC4 (0.39) | GRM5DDB1CRBNKMT2A | |
| SCHEMBL21452380 | 0.85 | OPRM1 (0.39) | GRM5SLC6A4RORCDDB1CRBN | |
| SCHEMBL26451027 | 0.84 | KMT2A (0.38) | RORCDDB1CRBNKMT2A | |
| SCHEMBL21452133 | 0.84 | SLC6A4 (0.41) | SLC6A2SLC6A4KMT2A | |
| SCHEMBL25381871 | 0.84 | SIRT2 (0.38) | SIRT2SIRT1DRD2KDM4DSLC6A2 | |
| SCHEMBL21452492 | 0.84 | SIRT2 (0.38) | SIRT2SIRT1DRD2KDM4DSLC6A2 | |
| SCHEMBL31426669 | 0.84 | SIRT2 (0.38) | SIRT2SIRT1DRD2KDM4DSLC6A2 | |
| SCHEMBL21452431 | 0.83 | RXFP1 (0.39) | GRM5SLC6A4CNR2 | |
| SCHEMBL21452014 | 0.83 | CYP11B2 (0.39) | DRD2KDM4DABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171487-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JIANHE PHARMACEUTICAL & TECHNOLOGY CO. LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| EP-3778579-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jianhe Pharmaceutical & Technology Co. Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019192602-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海键合医药科技有限公司 | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171487-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, PAH, COMT | SIRT2 4229/4885SIRT1 3033/4885GRM5 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.